CellWell record HH-580330
Oral mucositis risk with EGFR tyrosine kinase inhibitor monotherapies and combination regimens in non-small cell lung cancer: a systematic review and network meta-analysis
Huiwen Sun; Yifan Yao; Xinyu Liu; Ruiyi Qiu; Jinhan Chen; Gaochenxi Zhang; Qijin Shu
2026
In plain language
Oral mucositis risk varied across EGFR tyrosine kinase inhibitor regimens in 63 trials of lung cancer, with several regimens including afatinib-based ones showing higher odds than chemotherapy.
- Evidence
- Established
- Design
- Meta-analysis
Cite this record: https://thecellwell.org/studies/HH-580330
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.